Yield10 Bioscience to Present at the 8th annual LD Micro Invitational

May 29, 2018 8:30 AM

WOBURN, MA / ACCESSWIRE / May 29, 2018 / Yield10 Bioscience, Inc. (NASDAQ: YTEN), a company focused on developing new technologies to achieve step-change improvements to crop yield to enhance global food security, announced today that Oliver Peoples, Ph.D., President and Chief Executive Officer of Yield10, will be presenting at the 8th Annual LD Micro Invitational Conference on Tuesday, June 5, 2018 at 4:30 pm PST/7:30 pm EST. Management will...

Read more

American Premium Water Corp.’s (OTC:HIPH) Recaps Successful 1st Quarter Amid Planned Growth Initiatives for Rest of 2018

May 29, 2018 6:00 AM

Company announces Q1 Results 2018; Over 7400% growth compared to Q1 2017 PLAYA VISTA., CA / ACCESSWIRE / May 29, 2018 / American Premium Water Corporation (OTC PINK: HIPH) ("APWC") completed a successful first quarter expanding distribution, cultivating partnerships, and laying the foundation for a successful fiscal year by releasing Q1 financials showing quadruple digit growth in comparison to the same period last year, with a 7401% growth in...

Read more

MorphoSys to Present at Upcoming Investor Conferences

May 18, 2018 8:50 AM

PLANEGG and MUNICH, GERMANY / ACCESSWIRE / May 18, 2018 / MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC PINK: MPSYY; NASDAQ: MOR) will present at the following conferences: UBS Global Healthcare Conference Date: May 21, 2018, 11:00 am EDT (5:00 pm CEST, 4:00 pm BST) Venue: New York, NY, US Presenter: Jens Holstein, Chief Financial Officer of MorphoSys AG Dr. Claudia Gutjahr-Löser, Investor Relations Officer Berenberg...

Read more

Oncolix, Inc. to Present at the 8Th Annual LD Micro Invitational

May 17, 2018 5:45 PM

LOS ANGELES, CA / ACCESSWIRE / May 17, 2018 / Oncolix, Inc. (OTCQB: ONCX), a biopharmaceutical company focused on women's cancers, today announced that it will be presenting at the 8th annual LD Micro Invitational on Monday, June 4 at 9:30 AM, PST / 12:30 PM EST. Michael T. Redman, CEO, will be giving the presentation and meeting with investors. "Oncolix looks forward to attending its third LD Micro event," stated Michael T. Redman, CEO of...

Read more

Annual General Meeting of MorphoSys AG Elects New Supervisory Board Members

May 17, 2018 4:25 PM

All Resolutions Proposed by the Company's Management Approved PLANEGG and MUNICH, GERMANY / ACCESSWIRE / May 17, 2018 / MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC PINK: MPSYY; NASDAQ: MOR) announced today that its shareholders approved all resolutions proposed by the company's Management at its Annual General Meeting (AGM) which took place in Munich on Thursday, May 17, 2018, including: The discharge of the members of the...

Read more

MorphoSys Announces Presentation of Clinical Data on Proprietary Blood Cancer Programs at Upcoming EHA 2018 Conference

May 17, 2018 9:20 AM

PLANEGG and MUNICH, GERMANY / ACCESSWIRE / May 17, 2018 / MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC PINK: MPSYY; NASDAQ: MOR) today announced the publication of two abstracts on its proprietary hemato-oncological drug candidates MOR208 and MOR202 submitted to the 23rd European Hematology Association (EHA) Annual Meeting, to be held in Stockholm/Sweden from June 14-17, 2018. In a poster presentation, first clinical data from the...

Read more

Molecular Partners to Present Final MP0250 Phase 1 Data at ASCO Annual Meeting 2018

May 16, 2018 1:00 AM

ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE / May 16, 2018 / Molecular Partners AG (SIX: MOLN), a clinical-stage biopharmaceutical company developing a new class of drugs known as DARPin® therapies, announced today that the complete safety and efficacy results of the Phase 1 study of its lead proprietary oncology drug, MP0250, will be presented at the Annual Meeting 2018 of the American Society of Clinical Oncology (ASCO) in Chicago. MP0250...

Read more

Pressure BioSciences, Inc. Reports First Quarter 2018 Financial Results and Provides Business Update

May 15, 2018 12:25 PM

- Total Revenue, Products & Services Revenue, Instrument and Consumable Sales All Increased Y/Y; BaroFold IP Acquisition, Collaborations, Expanded Sales Team Expected to Fuel Growth. - Company Announces Conversion of $6.39M of Convertible Debentures into Equity - Investor Conference Call Scheduled for Tuesday, May 15, 2018 at 4:30 PM EDT SOUTH EASTON, MA / ACCESSWIRE / May 15, 2018 / Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the...

Read more

Pressure BioSciences, Inc. to Discuss First Quarter 2018 Financial Results and Provide Business Update

May 15, 2018 7:41 AM

SOUTH EASTON, MA / ACCESSWIRE / May 15, 2018 / Pressure BioSciences, Inc. (OTCQB: PBIO) (''PBI'' and the ''Company'') today announced that the Company will host a teleconference to discuss its First Quarter 2018 financial results and to provide a business update. Anyone interested may listen to the teleconference either live (by telephone) or through a replay (by telephone or via a link on the Company's website approximately one day after the...

Read more

Pressure BioSciences, Inc. Announces First Contract Utilizing Recently Acquired High Pressure Technology from BaroFold, Inc.

May 3, 2018 11:10 AM

International Biopharma Client to Evaluate PBI's Patented PreEMT™ Platform to Enhance Manufacturing Process and Improve Quality of Key Protein Therapeutic Drug Candidate SOUTH EASTON, MA / ACCESSWIRE / May 3, 2018 / Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" and the "Company"), a leader in the development and sale of innovative, broadly enabling, high pressure-based instruments and related consumables for the worldwide life sciences...

Read more

Vitro Bio-Pharma Debt Re-Capitalization and Executive Team Formation

May 3, 2018 9:30 AM

GOLDEN, CO / ACCESSWIRE / May 3, 2018 / Vitro Diagnostics, Inc. (OTCQB: VODG), dba Vitro BioPharma, announced today the details of its balance sheet re-capitalization and the formation of its executive team effective April 30th 2018. The company reorganized $1,003,119 of the company's founder and C.E.O. advances to the company that were advanced during the Research and Development years of the company over the last ten plus years. As previously...

Read more

MorphoSys AG Reports First Quarter 2018 Results

May 2, 2018 4:25 PM

Conference call and webcast (in English) to be held on May 3, 2018, at 2:00pm CEST (1:00pm BST/8:00am EDT) - Successful capital increase and U.S. Nasdaq listing closed in April 2018 with total gross proceeds of USD 239.0 million - MOR208: Updated data in DLBCL presented, constructive discussions with FDA regarding path to market for MOR208 under current breakthrough therapy designation ongoing - Tremfya(R): Partner Janssen received approvals in...

Read more

Pressure BioSciences, Inc., a Leader in the Development & Sale of Pressure-Based Solutions for the Worldwide Life Sciences Market, to Host Webinar Update for Investors

May 2, 2018 8:35 AM

Company to Discuss Expected Impact on 2018 Revenue from Recent Product Enhancements, New Field Salesforce, BaroFold Technology Asset Acquisition, and Newly Issued Patents SOUTH EASTON, MA / ACCESSWIRE / May 2, 2018 / Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" and the "Company"), a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences industry, today...

Read more

MorphoSys and Galapagos Announce Initiation of the IGUANA Phase 2 Clinical Trial with MOR106 in Atopic Dermatitis Patients

May 1, 2018 4:30 PM

PLANEGG and MUNICH, GERMANY and MECHELEN, BELGIUM / ACCESSWIRE / May 1, 2018 / MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; NASDAQ: MOR; OTC: MPSYY) and Galapagos NV (GLPG) announced today that the first patient has been enrolled in IGUANA, a phase 2 study with MOR106, an investigational antibody directed against IL-17C, in atopic dermatitis patients. IGUANA - A MOR106 phase 2 trial At least 180 patients with moderate-to-severe atopic...

Read more

Qrons Inc. Engages American Capital Ventures for Investor Relations Services

April 30, 2018 9:00 AM

MIAMI, FL / ACCESSWIRE / April 30, 2018 / Qrons Inc., (www.Qrons.com) (OTC PINK: QRON) a preclinical biotechnology company that is developing advanced cell-based solutions to combat neurological injuries today announced that it has engaged American Capital Ventures ("ACV"), a boutique provider of comprehensive investor relations services to micro- and small-cap companies, to provide investor relations services to the company. Jonah Meer, CEO of...

Read more

MorphoSys Announces Approval of Tremfya(R) (Guselkumab) in South Korea

April 26, 2018 4:30 PM

PLANEGG and MUNICH, GERMANY / ACCESSWIRE / April 26, 2018 / MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC PINK: MPSYY; NASDAQ: MOR) announced today that an affiliate of its licensee, Janssen Korea Ltd. (Janssen), reported that South Korea's Ministry of Food and Drug Safety has approved Tremfya(R) (guselkumab) for the treatment of moderate to severe adult plaque psoriasis requiring phototherapy or systemic therapies. Tremfya(R) is a...

Read more

Further MP0250 Clinical Data and Partner Interest Underline Molecular Partners' Continued Progress of Its Proprietary Oncology Compounds

April 26, 2018 1:00 AM

Research & Development: MP0250 in multiple myeloma (MM): Promising initial safety and efficacy data from the ongoing phase 2 study of MP0250 reconfirmed with updated data presented at the European Myeloma Network Meeting in Turin on April 21 MP0250 in EGFR-mutated Non-Small Cell Lung Cancer (EGFR mut NSCLC): Collaboration with AstraZeneca for ongoing phase 1b/2 clinical study of MP0250 with osimertinib (Tagrisso®) announced...

Read more

MorphoSys to Host Q1 2018 Conference Call on May 3, 2018

April 25, 2018 10:00 AM

PLANEGG/MUNICH, GERMANY / ACCESSWIRE / April 25, 2018 / MorphoSys AG (FSE: MOR) (XETRA: MOR) (OTC PINK: MPSYY) will publish its first three months' 2018 results on May 2nd, 2018 at 10:00 p.m. CEST (4 p.m. EDT; 9 p.m. BST). The Management team of MorphoSys AG will host a conference call and webcast on May 3rd, 2018 at 2:00 p.m. CEST to present MorphoSys's first quarter interim statement 2018 and provide an outlook for 2018. Date of the conference...

Read more

MorphoSys AG: Updated Corporate Calendar 2018

April 25, 2018 9:55 AM

PLANEGG/MUNICH, GERMANY PLANEGG and MUNICH, GERMANY / ACCESSWIRE / April 25, 2018 / Please note MorphoSys's updated financial reporting dates for the remainder of 2018. After the successful listing at Nasdaq, the reporting dates have been updated as follows, in order to make the information available to all shareholders and stakeholders of MorphoSys in the best possible way: Publication of Interim...

Read more

GoX Studio Introduces GoX Ergo, Wearable Sensors to Improve Worker Wellness and Safety

April 24, 2018 11:13 AM

GoX Ergo is the Only Sensor Kit on the Market That Measures Form, Fatigue, Force, and Rate of Perceived Exertion from the User. PHOENIX, AZ / ACCESSWIRE / April 24, 2018 / Wearable sensors and innovative algorithms are now able to protect factory workers from bad lifts and overexertion that increase the risk of injury. GoX Studio, an innovator in worker assessment using proprietary wearable sensors and algorithms, has developed the most...

Read more